Pericardial, retroperitoneal and pleural fibrosis induced by pergolide

A Wilkins

Research output: Contribution to journalArticle (Academic Journal)peer-review

99 Citations (Scopus)


Three patients with Parkinson's disease are described who developed pericardial, retroperitoneal, and pleural fibrosis associated with pergolide treatment. Surgical intervention was required in all three cases, either to reach a tissue diagnosis or for potentially life threatening complications. Symptoms emerged on average 2 years after the institution of treatment, and were sufficiently non-specific to cause significant delays in diagnosis in all cases. The erythrocyte sedimentation rate (ESR) was raised in the two patients in whom it was measured. Serosal fibrosis is a rarely reported adverse effect of pergolide treatment, although it is well described with other dopamine agonists. We suggest that patients with Parkinson's disease who receive pergolide treatment should be regularly monitored for the development of such complications.
Translated title of the contributionPericardial, retroperitoneal and pleural fibrosis induced by pergolide
Original languageEnglish
Pages (from-to)79 - 81
JournalJournal of Neurology, Neurosurgery, and Psychiatry
Publication statusPublished - 1999

Bibliographical note

Author of Publication Reviewed: Shaunak S, Wilkins A, Pilling JB, Dick DJ


Dive into the research topics of 'Pericardial, retroperitoneal and pleural fibrosis induced by pergolide'. Together they form a unique fingerprint.

Cite this